Cargando…

Cost–Effectiveness Analysis of Dapagliflozin Plus Standard Treatment for Patients With Type 2 Diabetes and High Risk of Cardiovascular Disease in China

PURPOSE: To evaluate the long-term cost-effectiveness of dapagliflozin, in addition to standard treatment, for the treatment of adult patients with type 2 diabetes (T2DM) at high cardiovascular risk from the Chinese healthcare system perspective. METHODS: A decision-analytic Markov model with one-ye...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Kaiyu, Wang, Yao, Sun, Sijia, Zhu, Qian, Zhou, Weifeng, Liu, Jiatao, Zhu, Dongchun, Xie, Xuefeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Public Health
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9326075/ https://www.ncbi.nlm.nih.gov/pubmed/35910934 http://dx.doi.org/10.3389/fpubh.2022.936703

Ejemplares similares

Cost-effectiveness analysis of camrelizumab plus chemotherapy as first-line treatment for advanced squamous NSCLC in China
por: Shao, Taihang, et al.
Publicado: (2022)

Cost-effectiveness of two screening strategies based on Chinese diabetes risk score for pre-diabetes in China
por: Hao, Jingjing, et al.
Publicado: (2022)

Cost-Effectiveness of Avelumab Maintenance Therapy Plus Best Supportive Care vs. Best Supportive Care Alone for Advanced or Metastatic Urothelial Carcinoma
por: Xie, Qian, et al.
Publicado: (2022)

Cost-effectiveness analysis of durvalumab plus chemotherapy as first-line treatment for biliary tract cancer
por: Ye, Zhuo-miao, et al.
Publicado: (2023)

Atezolizumab Plus Chemotherapy vs. Chemotherapy in Advanced or Metastatic Triple-Negative Breast Cancer: A Cost-Effectiveness Analysis
por: Liu, Xiaoyan, et al.
Publicado: (2021)

Corrigendum: Cost-effectiveness of avelumab maintenance therapy plus best supportive care vs. best supportive care alone for advanced or metastatic urothelial carcinoma
por: Xie, Qian, et al.
Publicado: (2022)

Measuring the importance of influencing factor for COVID-19 vaccination intention in China
por: Su, Yue, et al.
Publicado: (2023)

Health care costs of cardiovascular disease in China: a machine learning-based cross-sectional study
por: Lu, Mengjie, et al.
Publicado: (2023)

Cost‐effectiveness of adding dapagliflozin to standard treatment for heart failure with reduced ejection fraction patients in China
por: Yao, Younan, et al.
Publicado: (2020)

Predicting incidence of hepatitis E for thirteen cities in Jiangsu Province, China
por: Wu, Tianxing, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy vs. Chemotherapy Alone as First-Line Treatment in Patients With Esophageal Squamous Cell Carcinoma and PD-L1 CPS of 10 or More
por: Zheng, Zhiwei, et al.
Publicado: (2022)

Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease
por: Reifsnider, Odette S, et al.
Publicado: (2021)

Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC
por: Chen, Pingyu, et al.
Publicado: (2022)

The impact of adult children rural–urban migration on left-behind parents' health: Evidence from China
por: Zhang, Chi, et al.
Publicado: (2022)

Effects of air pollution on cardiovascular health in patients with type 2 diabetes mellitus: Evidence from a large tertiary hospital in Shandong Province, China
por: Zhang, Jitian, et al.
Publicado: (2022)

Cost-effectiveness analysis of colonoscopy and fecal immunochemical testing for colorectal cancer screening in China
por: Ren, Yinan, et al.
Publicado: (2022)

Knowledge, Attitude, and Perceived Barriers of Newly Graduated Registered Nurses Undergoing Standardized Training in Intensive Care Unit Toward Early Mobilization of Mechanically Ventilated Patients: A Qualitative Study in Shanghai
por: Jiang, Jinxia, et al.
Publicado: (2022)

Lenvatinib Plus Pembrolizumab vs. Chemotherapy in Pretreated Patients With Advanced Endometrial Cancer: A Cost-Effectiveness Analysis
por: Feng, Mingyang, et al.
Publicado: (2022)

Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma
por: Ye, Zhuo-miao, et al.
Publicado: (2022)

Perspective and Experience of Male Nursing Students in 3-year Vocational College During Their Clinical Practicum: A Qualitative Study in Shanghai, China
por: Liu, Yue, et al.
Publicado: (2022)

The Development of a Competency Assessment Standard for General Practitioners in China
por: Rao, Xin, et al.
Publicado: (2020)

Characteristics, risk management and GMP standards of pharmaceutical companies in China
por: Chen, Hong, et al.
Publicado: (2023)

Examining standardized tools used for the evaluation of mobile health applications for cardiovascular disease
por: Kircher, Jennifer, et al.
Publicado: (2023)

Economic evaluation of first-line nivolumab plus cabozantinib for advanced renal cell carcinoma in China
por: Wang, Hao, et al.
Publicado: (2022)

Sugemalimab plus chemotherapy vs. chemotherapy for metastatic non-small-cell lung cancer: A cost-effectiveness analysis
por: Liang, Xueyan, et al.
Publicado: (2023)

Research on Financing Mechanism of Long-Term Care Insurance in Xiamen, China: A System Dynamics Simulation
por: Zhang, Liangwen, et al.
Publicado: (2021)

Cost–Utility Analysis of Dapagliflozin as an Add-On to Standard Treatment for Patients with Type 2 Diabetes and High Risk of Cardiovascular Disease in Thailand
por: Deerochanawong, Chaicharn, et al.
Publicado: (2021)

Evaluating the Cost-Effectiveness of Proportional-Assist Ventilation Plus vs. Pressure Support Ventilation in the Intensive Care Unit in Two Countries
por: Saunders, Rhodri, et al.
Publicado: (2018)

Cost-effectiveness analysis of vaccination against COVID-19 in China
por: Zhou, Huixuan, et al.
Publicado: (2023)

Cost of Illness, Quality of Life, and Work Outcomes in Active Ankylosing Spondylitis Patients Treated With Adalimumab in China
por: Tu, Liudan, et al.
Publicado: (2020)

Cost-Effectiveness of Population Screening Programs for Cardiovascular Diseases and Diabetes in Low- and Middle-Income Countries: A Systematic Review
por: Sharma, Manushi, et al.
Publicado: (2022)

How does diabetic peripheral neuropathy impact patients' burden of illness and the economy? A retrospective study in Beijing, China
por: Pan, Qi, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Gefitinib Alone and Combined with Chemotherapy as First-Line Treatment for Patients with Advanced Non-Small-Cell Lung Cancer
por: Wang, Yao, et al.
Publicado: (2022)

Coping with COVID: Performance of China’s hierarchical medical system during the COVID-19 pandemic
por: Yang, Yong, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Pan-Genotypic Sofosbuvir-Based Regimens for Treatment of Chronic Hepatitis C Genotype 1 Infection in China
por: Zhou, Hui Jun, et al.
Publicado: (2021)

Research on the optimization of financing scheme of long-term care insurance in China based on system dynamics simulation
por: Zhang, Liangwen, et al.
Publicado: (2022)

Living Alone Is Not Associated With Cardiovascular Events and Hypoglycemia in Patients With Type 2 Diabetes Mellitus
por: Zhu, Zhaowei, et al.
Publicado: (2022)

Exploring the Mediating Effect of Physical Activities on Built Environment and Obesity for Elderly People: Evidence From Shanghai, China
por: Xiao, Yang, et al.
Publicado: (2022)

Regional and epidemiological characteristics of tuberculosis and treatment outcomes in West China
por: Wang, Qiaolan, et al.
Publicado: (2023)

How to Make a Cost Model for the Birth Cohort Biobank in China
por: Wu, Meiqin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_q8rlfebk1rmh80lq2b19ek7oej